CR20140326A - Composiciones farmacéuticas tópicas que comprenden bexateno y corticosteroides - Google Patents

Composiciones farmacéuticas tópicas que comprenden bexateno y corticosteroides

Info

Publication number
CR20140326A
CR20140326A CR20140326A CR20140326A CR20140326A CR 20140326 A CR20140326 A CR 20140326A CR 20140326 A CR20140326 A CR 20140326A CR 20140326 A CR20140326 A CR 20140326A CR 20140326 A CR20140326 A CR 20140326A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
bexateno
corticosteroids
topical pharmaceutical
compositions
Prior art date
Application number
CR20140326A
Other languages
English (en)
Inventor
Fritjof Evers
Sabine Fielhauer
Henning Mallwitz
Hagen Trommer
Christoph Willers
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48781060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP12000077.3A external-priority patent/EP2612665A1/en
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CR20140326A publication Critical patent/CR20140326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones farmacéuticas tópicas que comprenden: a) bexaroteno, b) un corticosteroide, yc) un portador o vehículo. Dichas composiciones son útiles para el tratamiento de trastornos de la piel.
CR20140326A 2012-01-09 2014-07-08 Composiciones farmacéuticas tópicas que comprenden bexateno y corticosteroides CR20140326A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12000077.3A EP2612665A1 (en) 2012-01-09 2012-01-09 Topical pharmaceutical compositions comprising bexarotene and a corticosteroide
US201261585786P 2012-01-12 2012-01-12
EP12000909 2012-02-13
PCT/EP2012/005237 WO2013104399A1 (en) 2012-01-09 2012-12-18 Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
US201461598095P 2014-02-13 2014-02-13

Publications (1)

Publication Number Publication Date
CR20140326A true CR20140326A (es) 2015-01-16

Family

ID=48781060

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140326A CR20140326A (es) 2012-01-09 2014-07-08 Composiciones farmacéuticas tópicas que comprenden bexateno y corticosteroides

Country Status (21)

Country Link
US (1) US20140349981A1 (es)
EP (1) EP2802321A1 (es)
JP (1) JP2015503573A (es)
KR (1) KR20140107370A (es)
CN (1) CN104053437A (es)
AU (1) AU2012365658A1 (es)
BR (1) BR112014015578A8 (es)
CA (1) CA2857207A1 (es)
CL (1) CL2014001776A1 (es)
CO (1) CO7000772A2 (es)
CR (1) CR20140326A (es)
EA (1) EA201400806A1 (es)
GT (1) GT201400146A (es)
HK (1) HK1198423A1 (es)
IL (1) IL232765A0 (es)
MX (1) MX2014007300A (es)
PE (1) PE20142375A1 (es)
PH (1) PH12014501573A1 (es)
SG (1) SG11201403762PA (es)
WO (1) WO2013104399A1 (es)
ZA (1) ZA201403483B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909884T3 (es) 2013-08-20 2022-05-10 Univ Washington Through Its Center For Commercialization Inhibidores nuevos y específicos de la hidroxilasa del ácido retinoico del citocromo P450 26
AU2016279801B2 (en) * 2015-06-18 2021-09-09 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
WO2020069448A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of steroids and large molecules
CA3117842A1 (en) * 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4387463B2 (ja) 1997-02-20 2009-12-16 アラーガン、インコーポレイテッド タザロテンおよびコルチコステロイドによる乾癬の処置
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
CN1210035C (zh) 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物

Also Published As

Publication number Publication date
EA201400806A1 (ru) 2015-02-27
GT201400146A (es) 2015-10-12
PE20142375A1 (es) 2015-01-11
KR20140107370A (ko) 2014-09-04
ZA201403483B (en) 2015-06-24
PH12014501573A1 (en) 2014-10-08
MX2014007300A (es) 2014-07-28
CA2857207A1 (en) 2013-07-18
EP2802321A1 (en) 2014-11-19
BR112014015578A2 (pt) 2017-06-13
SG11201403762PA (en) 2014-07-30
WO2013104399A1 (en) 2013-07-18
US20140349981A1 (en) 2014-11-27
IL232765A0 (en) 2014-07-31
AU2012365658A1 (en) 2014-07-03
CL2014001776A1 (es) 2014-08-29
JP2015503573A (ja) 2015-02-02
BR112014015578A8 (pt) 2017-07-04
CN104053437A (zh) 2014-09-17
CO7000772A2 (es) 2014-07-21
HK1198423A1 (en) 2015-04-24

Similar Documents

Publication Publication Date Title
CL2017003404A1 (es) Compuestos antibacterianos
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CL2017000817A1 (es) Triazolopirazinonas como inhibidores de pde1
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CR20140326A (es) Composiciones farmacéuticas tópicas que comprenden bexateno y corticosteroides
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
EA032472B9 (ru) Композиция для укладки волос
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
IN2013MU03118A (es)
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
GT201600190A (es) Compuestos químicos
BR112015021410A2 (pt) inibidores macrocíclicos das interações das proteína/proteína pd-1/pd-l1 e cd80(b7-1)/pd-l1